Tenecteplase Reperfusion Therapy in Acute Ischaemic Cerebrovascular Events-5 (TRACE-5)
Tenecteplase Reperfusion Therapy in Acute Ischaemic Cerebrovascular Events-5 Improving Neurological Functional Outcomes in Basilar Artery Occlusion With Tenecteplase in Extended Time Window: Multicentre, Prospective, Open-label, Blinded Endpoint (PROBE), Phase 3, Randomized Controlled Trial
Sponsor: Beijing Tiantan Hospital
This PHASE3 trial investigates Ischemic Stroke, Acute and is currently completed. Beijing Tiantan Hospital leads this study, which shows 6 recorded versions since 2024 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
6 versions recorded-
Dec 2025 — Present [monthly]
Completed PHASE3
-
Oct 2025 — Dec 2025 [monthly]
Completed PHASE3
Status: Recruiting → Completed
-
May 2025 — Oct 2025 [monthly]
Recruiting PHASE3
-
Sep 2024 — May 2025 [monthly]
Recruiting PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE3
▶ Show 1 earlier version
-
Feb 2024 — Jul 2024 [monthly]
Recruiting PHASE3
First recorded
Jan 2024
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Beijing Tiantan Hospital
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Anyang, China , Baoding, China , Beijing, China , Changchun, China , Chenzhou, China , Dongying, China , Fuyang, China , Gaomi, China , Guangzhou, China , Guiyang, China and 40 more locations